India’s pharmaceutical giant, Dr Reddy’s Laboratories today launched Avigan (Favipiravir’s revolutionary brand) 200 mg COVID patient care tablets in India. Avigan has been approved for treating patients with mild to moderate COVID-19 disease by the Drugs Controller General of India (DCGI).
Dr. Reddy’s said it launched a free home delivery service in 42 cities across the country, and a helpline center at 1800-267-0810 / www.readytofightcovid.in by 9 a.m. to ensure fast access to the drug. Till 9 p.m. IST, Saturdays through Mondays.
The launch is a part of FUJIFILM Toyama Chemical Co ‘s global licensing agreement. Ltd. that grants Dr. Reddy’s exclusive rights in India to produce, sell and distribute 200 mg AVIGAN (Favipiravir) tablets, it said.
“We are pleased to bring this important innovator medicine to the patients in India. The need for high quality and efficacy, affordability and better disease management are key priorities for us. We believe that Avigan would provide an effective treatment option to the COVID-19 impacted patients in India,” said MV Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr Reddy’s Laboratories.
Dr Reddy’s Avigan arrives in a complete 122 tablet therapy pack with a two-year shelf life. Top drug makers like Lupin, Glenmark and Sun Pharma have already released a generic version of the antiviral medication favipiravir in India for the treatment of COVID-19. Favipiravir and another anti-viral medication, remdesivir, have emerged as India’s most sought-after medicines for the treatment of COVID-19, which had already authorized the medicines as emergency therapies to tackle the outbreak.